The Personalised mRNA Melanoma Vaccine: What Patients Need to Know

This is the question we have been asked most often in the clinic over the past week, usually in some version of: does this mean I won’t get melanoma? or should I be asking for this?

The honest answers are no and — for almost everyone reading this — not yet. But the science behind it is genuinely significant, and it is worth understanding properly rather than through headlines. This page sets out what the treatment is, what the trials actually measured, which patients the evidence covers, and where things stand in Australia.

What is the “melanoma vaccine”?

Intismeran autogene — previously called V940 or mRNA-4157 — is an individualised neoantigen therapy.⁽⁴⁾ This is a genuinely new way of creating patient-specific cancer therapies that will hopefully find its way into many other cancer types over time.

A neoantigen is an abnormal marker produced by a mutation inside a cancer cell. Because these markers are not found on normal cells, they make useful targets: they give the immune system something specific to recognise. After a melanoma is surgically removed, the tumour can be genetically sequenced and compared against the patient’s normal cells. Computational methods then pick the mutations judged most likely to provoke an immune response, and up to 34 of those targets are encoded into a strand of synthetic messenger RNA (mRNA) manufactured for that one person.⁽¹⁾

The result is given by intramuscular injection over a course of doses. The mRNA supplies temporary instructions that teach immune cells what those selected melanoma markers look like. It does not permanently change a patient’s DNA.

How is this different from an ordinary vaccine?

The word vaccine is doing a lot of confusing work here. Almost every vaccine people have encountered is preventive — given before an infection, to stop it happening. Intismeran autogene is therapeutic: it cannot exist until a person has developed a cancer, because it is built out of that cancer.

It does not prevent sun damage, does not stop a new melanoma forming somewhere else on the skin, and does not replace sun protection or regular skin checks.

Why is it given with pembrolizumab?

Pembrolizumab (Keytruda) is an established immunotherapy called a PD-1 checkpoint inhibitor. The immune system has built-in checkpoints — safety mechanisms that stop it attacking the body’s own healthy tissue. Melanoma is very good at abusing them. Pembrolizumab blocks one of those checkpoints so immune cells can keep working.

The two treatments do different jobs, which is why they are given together. It helps to picture the immune system as a police force, and the checkpoint as the moment an officer stops someone to check their credentials:

• The vaccine hands out the wanted photos. It gives the immune system a detailed description of that particular patient’s melanoma, so its cells know precisely who they are looking for.
• Pembrolizumab stops the search being called off. Melanoma cells carry what amounts to a forged ID card — a surface signal that tells an arriving immune cell “nothing to see here” and switches it off mid-search. Pembrolizumab blocks that signal, so the immune cells the vaccine has briefed are not stood down before they finish the job.

One treatment says who to look for; the other makes sure the search continues.

Both trials compared intismeran autogene plus pembrolizumab against pembrolizumab alone. Neither tested the vaccine on its own, and neither showed that it can replace pembrolizumab. It is an additional personalised layer built on top of an effective existing treatment — not a replacement for it.

What did the Phase 2 trial show?

The Phase 2b KEYNOTE-942 trial gave the first strong signal. It enrolled 157 adults, at sites in the United States and Australia, whose Stage IIIB–IV cutaneous melanoma had been completely removed. They were randomised 2:1 — 107 received the combination, 50 received pembrolizumab alone.⁽³⁾

The five-year update, published in the Journal of Clinical Oncology in June 2026, reported:⁽⁴⁾

Reading those numbers properly

The simplest way to picture the headline result: at five years, roughly 69 of every 100 patients in the combination group were estimated to be free of recurrence, compared with roughly 49 of every 100 on pembrolizumab alone. That is a difference of about 20 percentage points at the five-year mark.

The widely reported “49% reduction” is a reduction in the relative hazard of recurrence or death across the study. It does not mean any individual’s personal risk falls by 49 percentage points, and it is not a cure rate.

What about side effects?

This is not comparable to a routine flu jab. Effects attributed to the vaccine itself were mostly tiredness, injection-site pain and chills. In the Phase 2 publication, Grade 3 or worse treatment-related adverse events occurred in 25% of the combination group and 18% of the pembrolizumab-only group, with no Grade 4–5 events attributed to the vaccine. Immune-mediated adverse events occurred at essentially the same rate in both groups (36% each).⁽³⁾

It is a substantial cancer-treatment programme requiring specialist selection, blood tests, monitoring, and management of possible immunotherapy complications.

What has happened in the Phase 3 trial?

The Phase 3 trial is not “about to start” — it began in July 2023, finished recruiting some time ago, and reported top-line results on 19 August 2026.

INTerpath-001 enrolled 1,137 patients with completely resected Stage IIB, IIC, III or IV cutaneous melanoma, all with no detectable melanoma after surgery and no previous systemic treatment for it. They were randomised 2:1 to intismeran autogene plus pembrolizumab, or pembrolizumab alone. Six of its sites are in Australia, including two in Melbourne.^(1,2)

What was announced: the trial met its primary endpoint of recurrence-free survival and its key secondary endpoint of distant metastasis-free survival, with safety consistent with previous studies and no new safety signals. The companies describe it as the first positive Phase 3 readout for an individualised neoantigen therapy and for an mRNA-based cancer therapy.⁽¹⁾

What was not announced: any actual numbers. Nothing has been released about the size of the difference between the groups, how the benefit was distributed across the stages, the full adverse-event and discontinuation data, or overall survival — which the trial is continuing to follow.⁽¹⁾

A positive top-line press release tells you a trial succeeded on its own terms; it does not tell you by how much, or for whom. The detailed data need to be presented at a medical meeting and peer reviewed before the size of the benefit can be judged. Until then, the Phase 2 figures above are the best available guide, and they come from 157 patients, not 1,137.

Which patients does the evidence actually cover?

This is the question that matters most to anyone reading this after a melanoma diagnosis. The short version: the adjuvant evidence begins at Stage IIB.

Being inside the shaded band does not mean a patient will receive this treatment. Any future indication will depend on the complete results, regulatory approval, the individual’s health, the melanoma’s characteristics, and specialist assessment.

Does this change treatment for Stage 0 or Stage I melanoma?

For the overwhelming majority of people diagnosed with Stage 0 or Stage I melanoma — nothing changes.

Melanoma in situ (Stage 0) is confined to the outermost layer of the skin and has not invaded deeper, so it has no route to spread. Thin invasive melanoma (typically Stage I) has begun to invade but remains early and localised, with no evidence of spread to lymph nodes or elsewhere.

Neither was included in the Phase 3 trial, and there is no evidence that adding a vaccine or pembrolizumab to appropriate surgery helps at these stages. Treatment remains:

1. complete removal of the melanoma;
2. a wider local excision with the appropriate margin where required;
3. regular examination of the skin and lymph nodes; and
4. ongoing prevention and early detection of further skin cancers.

There is a reason these stages were left out, and it is a reassuring one: the cure rate with surgery alone is already very high. The most useful thing a person with an early melanoma can do is keep attending surveillance — not seek an experimental treatment designed for a much higher-risk group.

Can Australian patients join a trial?

INTerpath-001 — no. The Phase 3 adjuvant trial is listed as active but not recruiting. It is fully enrolled; existing participants continue to be followed, but no new patients can join.⁽²⁾

INTerpath-012 — possibly, for a different situation. This separate Phase 2 study (NCT06961006) is recruiting people with previously untreated, unresectable Stage III or Stage IV cutaneous melanoma — melanoma that cannot be completely removed by surgery. It compares intismeran autogene plus pembrolizumab against placebo plus pembrolizumab. As at 23 August 2026 its listed Australian sites are in Sydney and Perth; there is currently no Victorian site.^(5,6)

If you have advanced melanoma and want to explore trial participation:

1. Start with your treating melanoma medical oncologist. Eligibility turns on your exact stage, whether the melanoma is surgically removable, previous treatment, general health and detailed laboratory criteria — none of which can be assessed from a web page.
2. Quote the trial identifier NCT06961006. There are several intismeran studies, and the identifier is what makes sure the team finds the right protocol.
3. Ask the team or trial site to confirm current recruitment. Sites open, pause and close; the live register is the only reliable source.
4. Expect formal screening. An expression of interest is not enrolment — the research team has to confirm every eligibility criterion.

When might it be available in Australia?

As at 23 August 2026, intismeran autogene is investigational. It is not registered for use in Australia and is not routine melanoma treatment anywhere. In their own announcement the companies said they plan to present the Phase 3 data and engage with regulators about filing submissions — which means, as at that date, no submission had yet been assessed by any regulator.⁽¹⁾

Several steps would normally have to follow before widespread Australian use: full publication of the trial results, regulatory assessment, establishment of tumour-sequencing and individual manufacturing pathways, and decisions about funding and access.

There is also a practical constraint that does not apply to ordinary medicines. Every dose is sequenced, designed and manufactured for one named patient. That is a fundamentally different supply problem from taking a box off a pharmacy shelf.

A realistic expectation is therefore years rather than months, with any earlier access likely confined to clinical trials or specialist centres. That is an informed expectation, not an announced timetable — and we will update this page when the position changes.

The bottom line

The personalised melanoma vaccine is best understood as a patient-specific extra layer added to surgery and pembrolizumab for selected higher-risk patients. It is not a preventive vaccine, and it is not a replacement for existing melanoma treatment.

• The Phase 2 results were encouraging and, importantly, held up over five years.
• The Phase 3 top-line result is a genuine milestone — but the full data are still needed before anyone can say how large the benefit is.
• A survival benefit has not been established; recurrence, not survival, is what has been shown to improve.
• The adjuvant evidence begins at Stage IIB, not Stage 0 or Stage I.
• For most early melanomas, treatment remains complete surgical excision with appropriate margins.
• It appears to complement pembrolizumab rather than replace it.
• Routine Australian access is not imminent.

None of this diminishes what matters most for the people we see every day. A melanoma found early and removed completely has an excellent outlook without any of this. The most powerful melanoma intervention available in Australia today is still a skin check that finds it early.

Concerned about a new or changing mole?

The Skin Doctor provides doctor-led skin checks, melanoma assessment and skin cancer treatment at Ivanhoe and Diamond Creek. A targeted spot check suits up to three specific lesions you are worried about; a full skin check is the better option for whole-body screening or a history of skin cancer.

Patients diagnosed with higher-risk melanoma are referred to, and co-managed with, an appropriate melanoma specialist team — which is also the correct route for any discussion about clinical trials or adjuvant treatment. We do not provide intismeran autogene or any other investigational melanoma therapy.

If you have noticed a mole that is new, changing, or simply different from your others, do not wait for it to declare itself — what to look for and how surveillance works is covered in our melanoma follow-up guide.